Vincent Rizzo: Beta Blocker Choice May Impact Portal Vein Thrombosis and Survival in Cirrhosis
Vincent Rizzo, Chief Department of Internal Medicine at Icahn School of Medicine at Mount Sinai, shared a post on LinkedIn about a recent article he and his colleagues co- authored, published in Liver International, adding:
“Latest article, just published yesterday in Liver International. large study, over 8,000 patients with potentially practice changing, meanin agful results. big, huge shoutout to the team!!!
here is the lay summary:
In patients with liver cirrhosis, beta-blockers are commonly used to reduce complications related to high blood pressure in the liver.
In this large real-world study, we found that one commonly used beta-blocker (propranolol) was associated with a higher risk of blood clots in the portal vein, while another (carvedilol) did not increase this risk and was linked to better survival.
These findings suggest that the choice of beta-blocker may significantly affect patient outcomes.”
Title: Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study
Authors: Hazem Abosheaishaa, Khaled Elfert, Mohammed Abusuliman, Abdellatif Ismail, Abdullah Olimy, Ahmed Elsayed Alzamzamy, Ahmed Omran, Vincent Rizzo, Mahmoud Nassar, Mohamed El-Kassas
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 29, 2026, 15:06Laurent Arnaud: Rare SLE Manifestations Demand More Than Rare Attention – Insights from The Lancet Rheumatology
-
Aug 29, 2026, 14:55Marco Vitolo: The Changing Landscape of Sex Differences in AF-Related Stroke
-
Aug 29, 2026, 14:54Hiteshi K.C. Chauhan: Should Patients with AF and Intermediate Stroke Risk Receive Anticoagulation?
-
Aug 29, 2026, 14:39C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
-
Aug 29, 2026, 14:04Günalp Uzun: DGTI 2026 New Insights in Platelet Immunology and Hemostasis
-
Aug 29, 2026, 13:59Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
-
Aug 29, 2026, 11:03Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines
-
Aug 29, 2026, 10:57Bartosz Hudzik: First RCT Evidence for a Long-Standing Guideline Gray Zone
-
Aug 29, 2026, 10:50Edward Lee Carter: Breakthrough Stroke Beyond ‘DOAC Failure’ – Risk Stratification Insights from ASPERA-R